ISTA Vitrase User Fee Date Extended
This article was originally published in The Pink Sheet Daily
FDA has extended ISTA's user fee date for the drug-spreading agent Vitrase to May 5
You may also be interested in...
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
Sepracor's television ads for its sleep aid Lunesta create brand recognition better than other new prescription drug direct-to-consumer ads, according to an analysis performed by IAG Research
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles